Noxopharm Ltd
Noxopharm Limited, a biotech company, engages in the discovering and developing treatments for cancer and inflammation, and mRNA vaccines in Australia. It develops Sofra, a platform that focuses on the development of immunomodulators for mRNA vaccines and mRNA therapeutics, as well as for the treatment of autoimmune diseases; and Chroma technology platform to develop CRO-67 dual-cell therapy drug… Read more
Noxopharm Ltd (NOX) - Net Assets
Latest net assets as of June 2025: AU$689.96K AUD
Based on the latest financial reports, Noxopharm Ltd (NOX) has net assets worth AU$689.96K AUD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$4.58 Million) and total liabilities (AU$3.89 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | AU$689.96K |
| % of Total Assets | 15.06% |
| Annual Growth Rate | -21.28% |
| 5-Year Change | -98.31% |
| 10-Year Change | N/A |
| Growth Volatility | 147.12 |
Noxopharm Ltd - Net Assets Trend (2016–2025)
This chart illustrates how Noxopharm Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Noxopharm Ltd (2016–2025)
The table below shows the annual net assets of Noxopharm Ltd from 2016 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | AU$689.96K | -87.44% |
| 2024-06-30 | AU$5.50 Million | -39.44% |
| 2023-06-30 | AU$9.07 Million | -62.38% |
| 2022-06-30 | AU$24.12 Million | -40.85% |
| 2021-06-30 | AU$40.78 Million | +216.76% |
| 2020-06-30 | AU$12.87 Million | +987.49% |
| 2019-06-30 | AU$-1.45 Million | -114.29% |
| 2018-06-30 | AU$10.15 Million | +311.26% |
| 2017-06-30 | AU$2.47 Million | -58.50% |
| 2016-06-30 | AU$5.95 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Noxopharm Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 7404567300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | AU$74.64 Million | 10817.35% |
| Other Comprehensive Income | AU$700.06K | 101.46% |
| Other Components | AU$1.00 | 0.00% |
| Total Equity | AU$689.96K | 100.00% |
Noxopharm Ltd Competitors by Market Cap
The table below lists competitors of Noxopharm Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Welsbach Technology Metals Acquisition Corp
NASDAQ:WTMA
|
$7.24 Million |
|
Agriculture & Natural Solutions Acquisition Corporation Warrant
NASDAQ:ANSCW
|
$7.24 Million |
|
Carnegie Clean Energy Limited
OTCQB:CWGYF
|
$7.24 Million |
|
Pick N Pay Stores Ltd
JSE:PIK
|
$7.25 Million |
|
Trinity Exploration & Production plc
PINK:TRXEF
|
$7.24 Million |
|
Renegade Gold Inc.
V:RAGE
|
$7.23 Million |
|
Comarch SA
WAR:CMR
|
$7.23 Million |
|
Bleuacacia Ltd
NASDAQ:BLEU
|
$7.23 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Noxopharm Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 5,495,144 to 689,963, a change of -4,805,181 (-87.4%).
- Net loss of 4,884,170 reduced equity.
- Other comprehensive income decreased equity by 229,703.
- Other factors increased equity by 308,692.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | AU$-4.88 Million | -707.89% |
| Other Comprehensive Income | AU$-229.70K | -33.29% |
| Other Changes | AU$308.69K | +44.74% |
| Total Change | AU$- | -87.44% |
Book Value vs Market Value Analysis
This analysis compares Noxopharm Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 25.86x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.34x to 25.86x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-06-30 | AU$0.18 | AU$0.06 | x |
| 2017-06-30 | AU$0.03 | AU$0.06 | x |
| 2018-06-30 | AU$0.10 | AU$0.06 | x |
| 2019-06-30 | AU$0.00 | AU$0.06 | x |
| 2020-06-30 | AU$0.09 | AU$0.06 | x |
| 2021-06-30 | AU$0.15 | AU$0.06 | x |
| 2022-06-30 | AU$0.08 | AU$0.06 | x |
| 2023-06-30 | AU$0.03 | AU$0.06 | x |
| 2024-06-30 | AU$0.02 | AU$0.06 | x |
| 2025-06-30 | AU$0.00 | AU$0.06 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Noxopharm Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -707.89%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -173.15%
- • Asset Turnover: 0.62x
- • Equity Multiplier: 6.64x
- Recent ROE (-707.89%) is below the historical average (-135.68%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -11.85% | -195756.94% | 0.00x | 1.04x | AU$-1.30 Million |
| 2017 | -123.44% | -2411.66% | 0.04x | 1.15x | AU$-3.29 Million |
| 2018 | -180.17% | -1994.85% | 0.06x | 1.43x | AU$-19.30 Million |
| 2019 | 0.00% | -299.22% | 0.87x | 0.00x | AU$-11.21 Million |
| 2020 | -2.11% | -3.29% | 0.41x | 1.56x | AU$-1.56 Million |
| 2021 | -22.92% | -166.66% | 0.12x | 1.17x | AU$-13.42 Million |
| 2022 | -77.40% | -343.86% | 0.20x | 1.10x | AU$-21.08 Million |
| 2023 | -165.94% | -250.52% | 0.59x | 1.12x | AU$-15.96 Million |
| 2024 | -65.11% | -149.07% | 0.35x | 1.23x | AU$-4.13 Million |
| 2025 | -707.89% | -173.15% | 0.62x | 6.64x | AU$-4.95 Million |
Industry Comparison
This section compares Noxopharm Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $31,815,679
- Average return on equity (ROE) among peers: -60.84%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Noxopharm Ltd (NOX) | AU$689.96K | -11.85% | 5.64x | $7.24 Million |
| Adalta Ltd (1AD) | $2.03 Million | -265.03% | 1.74x | $150.42K |
| Algorae Pharmaceuticals Ltd (1AI) | $2.88 Million | -33.65% | 0.18x | $9.99 Million |
| ACRUX Ltd (ACR) | $17.49 Million | -17.99% | 0.05x | $2.16 Million |
| Argenica Therapeutics Ltd (AGN) | $13.95 Million | -39.28% | 0.17x | $11.71 Million |
| Arovella Therapeutics Ltd (ALA) | $11.23 Million | -77.89% | 0.18x | $39.76 Million |
| Anatara Lifesciences Ltd (ANR) | $5.92 Million | -48.49% | 0.08x | $718.75K |
| Bio-Gene Technology Ltd (BGT) | $4.25 Million | -56.43% | 0.18x | $2.26 Million |
| BTC Health Ltd (BTC) | $11.34 Million | -4.81% | 0.03x | $331.31 |
| Cambium Bio Ltd (CMB) | $8.27 Million | -79.86% | 0.16x | $8.11 Million |
| Clinuvel Pharmaceuticals Ltd (CUV) | $240.81 Million | 15.02% | 0.13x | $249.32 Million |